Houlihan Lokey Advises KabaFusion

Houlihan Lokey is pleased to announce that KabaFusion, an operating company investment of Pritzker Private Capital (PPC), has been acquired by Novo Holdings A/S (Novo Holdings).

KabaFusion is a national provider of essential acute, chronic, and enteral home infusion therapies, licensed to serve patients in 44 states through its nationwide network of home infusion pharmacies and home health agencies. The company was founded in 2010 by Chief Executive Officer Dr. Sohail Masood, a pioneer in patient-focused intravenous immunoglobulin infusion therapies with more than 30 years of clinical experience. KabaFusion is dedicated to working proactively with patients, healthcare practitioners, and payors to provide comprehensive support before, during, and after treatment. KabaFusion employs nearly 1,500 dedicated employees, clinicians, and nurses.

PPC partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. PPC builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. PPC is a signatory to the United Nations Principles for Responsible Investment.

Novo Holdings is a leading international healthcare and life sciences investor wholly owned by the Novo Nordisk Foundation. Headquartered in Copenhagen with offices in Boston, San Francisco, and Singapore, Novo Holdings manages the assets of the Novo Nordisk Foundation with a focus on creating sustainable, long-term value. In addition to being the controlling shareholder in Novo Nordisk A/S and Novozymes A/S, Novo Holdings invests broadly in healthcare and life sciences companies at all stages of development. As a firm, Novo Holdings ultimately seeks to deliver returns that the Novo Nordisk Foundation can distribute for scientific, social, and humanitarian purposes.

This transaction further strengthens Houlihan Lokey’s market leadership in the pharmacy and infusion-related services sectors, becoming its sixth closed M&A transaction in this space since 2020. Houlihan Lokey's Healthcare Group is among the largest dedicated healthcare investment banking groups in the country.

Houlihan Lokey served as the exclusive financial advisor to KabaFusion and assisted in initiating, structuring, and negotiating the transaction on its behalf. If you would like more information about Houlihan Lokey or have any questions regarding the Healthcare Group's role in this transaction, please contact one of the team members listed.